# From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s Reckoning > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-industry-regulatory-enforcement-fda-actions/ > **Published:** 2026-04-23T23:53:46-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:03:50-04:00 > **Clinical Summary:** Explore cannabis industry regulatory enforcement and FDA actions impacting hemp beverage marketing and cannabinoid product claims. --- ✦ New CED Clinical Relevance #97 Landmark Clinical Evidence Peer-reviewed human research with direct implications for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice. PolicyHempSafetyIndustry Clinical Summary The cannabis industry’s expansion into mainstream beverage markets has created a regulatory enforcement crisis, with the FDA issuing cease-and-desist letters to companies making unsubstantiated therapeutic claims about hemp-derived cannabinoid products worth billions in annual sales. These products, often marketed with vague wellness language or explicit disease claims without clinical evidence, are reaching consumers through conventional retail channels where they compete with regulated pharmaceuticals and dietary supplements. The FDA’s enforcement actions highlight the gap between industry marketing practices and the current evidence base for cannabinoid efficacy, particularly regarding claims about anxiety, pain, sleep, and other conditions where patients may delay or forgo proven treatments. For clinicians, this regulatory landscape creates challenges in counseling patients who are already using or considering these products, as the quality, potency, and safety profiles remain largely unverified outside controlled clinical settings. Patients may be exposed to mislabeled products, inconsistent dosing, and unsubstantiated efficacy claims that undermine informed decision-making about their health. Clinicians should screen patients for use of hemp beverages and cannabinoid-containing products, remain informed about FDA enforcement actions, and help patients distinguish between marketing claims and [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) medicine. Dr. Caplan’s Take “We’re watching an industry outpace regulation in real time, and patients are caught in the middle—they’re buying products with wildly inconsistent cannabinoid content and making medical decisions based on marketing claims that have never been tested in humans, which is exactly the opposite of how I practice medicine.” Clinical Perspective The rapid commercialization of cannabis-derived products, particularly [hemp-derived cannabinoids](https://cedclinic.com/indiana-hemp-drug-ban-thc-product-access/) in beverages and supplements, has outpaced regulatory oversight and created a complex landscape for clinicians counseling patients about safety and efficacy. While these products are aggressively marketed as wellness solutions with minimal side effects, significant gaps remain regarding product standardization, labeling accuracy, and long-term safety data, especially concerning cannabinoid concentrations and potential drug interactions. Clinicians should recognize that the absence of FDA approval does not equate to safety, and that enforcement actions against manufacturers do not necessarily reach consumers already using these products. When patients report using cannabis-derived beverages or supplements, practitioners should inquire about specific cannabinoid content, concurrent medications, and underlying conditions that might increase vulnerability to adverse effects or interactions. A practical approach involves documenting use systematically, discussing evidence limitations transparently, and considering cannabis-derived products as part of a broader substance use 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+From+Billion-Dollar+Hemp+Drinks+to+FDA+Cease-and-Desist+Letters%3A+The+%3Cb%3ECannabis%3C%2Fb%3E+Industry%27s+...+%40drcaplan&url=https%3A%2F%2Fwww.theglobeandmail.com%2Finvesting%2Fmarkets%2Fmarkets-news%2FACCESS+Newswire%2F612739%2Ffrom-billion-dollar-hemp-drinks-to-fda-cease-and-desist-letters-the-cannabis-industry-s-reckoning-is-coming%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.theglobeandmail.com%2Finvesting%2Fmarkets%2Fmarkets-news%2FACCESS+Newswire%2F612739%2Ffrom-billion-dollar-hemp-drinks-to-fda-cease-and-desist-letters-the-cannabis-industry-s-reckoning-is-coming%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+From+Billion-Dollar+Hemp+Drinks+to+FDA+Cease-and-Desist+Letters%3A+The+%3Cb%3ECannabis%3C%2Fb%3E+Industry%27s+...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.theglobeandmail.com%2Finvesting%2Fmarkets%2Fmarkets-news%2FACCESS+Newswire%2F612739%2Ffrom-billion-dollar-hemp-drinks-to-fda-cease-and-desist-letters-the-cannabis-industry-s-reckoning-is-coming%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 35 Items — April 09, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-april-2026-digest/) - [CED Digest: 35 Items — April 02, 2026](https://cedclinic.com/cannabis-cannabinoids-cbd-and-cbg-therapeutic-effects/) - [CED Digest: 50 Items — April 02, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS Newswire/612739/from-billion-dollar-hemp-drinks-to-fda-cease-and-desist-letters-the-cannabis-industry-s-reckoning-is-coming/](https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS Newswire/612739/from-billion-dollar-hemp-drinks-to-fda-cease-and-desist-letters-the-cannabis-industry-s-reckoning-is-coming/) Further Reading Evidence Watch[What a New Infant Cohort Really Shows About Cannabis and Breastfeeding](https://cedclinic.com/breastfeeding-after-prenatal-cannabis-exposure/) CED Clinic Blog[Cannabinoids and Chronic Pain: 2025 Evidence Review](https://cedclinic.com/cannabinoids-chronic-pain-clinical-outcomes-2025/) Research Digest[Research Digest: 10 Recent Studies – April 22, 2026](https://cedclinic.com/recent-cannabinoid-clinical-research-april-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Can Cannabis Replace Opioids for Chronic Pain? A New Review Maps What We Know—and What Remains Uncertain](https://cedclinic.com/cannabinoid-analgesia-mechanisms-chronic-pain-2025/) Explore the current evidence and challenges in using cannabis as an alternative to opioids for [chronic pain management](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/). [Read More](https://cedclinic.com/cannabinoid-analgesia-mechanisms-chronic-pain-2025/) [Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by …](https://cedclinic.com/cannabis-pharmaceuticals-business-research-report-2026-an-111-1-billion-market-by/) Discover insights into the rapidly growing cannabis pharmaceuticals market and its regulatory landscape. [Explore Report](https://cedclinic.com/cannabis-pharmaceuticals-business-research-report-2026-an-111-1-billion-market-by/) Cannabis' challenge isn't regulation – it's enforcement – MJBizDaily An analysis of enforcement challenges facing the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) beyond regulatory frameworks. Learn More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).